Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | TK2 | O00142 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6272366 | 1.00 | TK1 (0.66) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL6272364 | 1.00 | TK1 (0.66) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL439723 | 1.00 | TK1 (0.66) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL20750697 | 1.00 | TK1 (0.66) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Water SCHEMBL9633588 | 0.99 | TK1 (0.65) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Water SCHEMBL9633592 | 0.99 | TK1 (0.65) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL7707472 | 0.92 | TK1 (0.58) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL15740099 | 0.89 | TK1 (0.64) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL4263793 | 0.89 | TK1 (0.64) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| SCHEMBL12047413 | 0.89 | TK1 (0.65) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| CN-116916936-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2023-10-20 | — | — | CN | claimed |
| CN-103687961-B | Methods and compositions for isothermal whole genome amplification | 赛雷纳（中国）医疗科技有限公司 | 2022-11-22 | — | — | CN | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| CN-111334562-A | Nucleic acid amplification method and kit containing modified primer | 合肥铼科生物科技有限公司 | 2020-06-26 | — | — | CN | claimed |
| EP-2705166-A1 | METHODS AND COMPOSITIONS FOR ISOTHERMAL WHOLE GENOME AMPLIFICATION | Celula Inc. (US) | 2014-03-12 | — | — | EP | claimed |
| WO-2012154614-A1 | METHODS AND COMPOSITIONS FOR ISOTHERMAL WHOLE GENOME AMPLIFICATION | CELULA, INC. (US) | 2012-11-15 | — | — | WO | claimed |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-18 | — | — | US | claimed |
| WO-1999027086-A1 | CHIMERIC ANTISENSE OLIGONUCLEOTIDES AGAINST TNF-ALPHA AND THEIR USES | BRAX GROUP LIMITED (GB) | 1999-06-03 | — | — | WO | claimed |
| EP-0857208-A2 | CHIMAERIC OLIGONUCLEOTIDES AND USES THEREOF IN THE IDENTIFICATION OF ANTISENSE BINDING SITES | Brax Genomics Limited (GB) | 1998-08-12 | — | — | EP | claimed |
| US-5763208-A | Oligonucleotides and their analogs capable of passive cell membrane permeation | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | claimed |
| WO-1998004575-A2 | LIPOPHILIC OLIGONUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | claimed |
| WO-1997049833-A1 | METHOD FOR PRODUCING HYBRIDISATION COMPLEXES WHOSE STABILITY IS SUBSTANTIALLY INDEPENDENT OF THE BASE COMPOSITION OF TWO HYBRIDISED NUCLEIC ACID MOLECULES | APPLIGENE-ONCOR S.A. (FR) | 1997-12-31 | — | — | WO | claimed |
| US-5633360-A | CONTAINS AT LEAST TWO NUCLEOSIDE RESIDUES AND INTERNUCLEOTIDE LINKAGES | GILEAD SCIENCES, INC. (US) | 1997-05-27 | — | — | US | claimed |
| WO-1997010332-A2 | CHIMAERIC OLIGONUCLEOTIDES AND USES THEREOF IN THE IDENTIFICATION OF ANTISENSE BINDING SITES | BRAX GENOMICS LIMITED (GB) | 1997-03-20 | — | — | WO | claimed |
| EP-0573479-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-15 | — | — | EP | claimed |
| WO-1992015693-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | claimed |
| EP-0272065-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-06-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | TK1 156/4885LMNA 233/4885SMN1; SMN2 58/4885 |
| US-20100292135-A1 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS | RECQL, DNA2, WRN | TK1 656/4885LMNA 305/4885SMN1; SMN2 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.